Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With <i>ERBB2</i>-Positive Metastatic Breast Cancer

Abstract

In this study, TTC therapy was associated with clinically meaningful outcomes in patients with ERBB2-positive MBC after previous trastuzumab-deruxtecan treatment, including those with brain metastases. Prospective data on optimal drug sequencing in this rapidly changing therapeutic landscape are needed.